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Abstract
The global prevalence of breast cancer in women illustrates the importance of
identifying factors that contribute to disease onset and progression. Endogenous and
environmental agents that interact with estrogen receptor alpha (ER) have been shown
to play a role in breast cancer etiology. Evidence from epidemiological studies and
animal models has suggested that cadmium, a heavy metal that can activate ER,
contributes to the development and progression of breast cancer. Additionally, our lab
previously showed that chronic cadmium exposure altered the expression of several ERresponsive genes and increased the malignancy of MCF7 breast cancer cells. Although
these studies support cadmium’s function as a hormone disrupter, the role of ER in
cadmium-induced breast cancer progression remains unclear. In this study, we
modulated the expression of ER in MCF7 cells after chronic cadmium exposure (Cd7
and Cd12) in order to understand its role in cadmium-induced gene expression, cell
growth, migration, and anchorage-independence. While all of the cancer phenotypes
analyzed were altered in MCF7, Cd7, and Cd12 cells after the permanent loss of ERα,
cell growth and migration ability were less affected in cadmium-adapted cells suggesting
chronic cadmium exposure reduces the dependency of MCF7 cells on ER for these
characteristics. Furthermore, analysis showed the transcript levels of classical and nonclassical ER-regulated genes were reduced in MCF7 cells after transient and permanent
modification of ER expression, while the non-classical targets were not as affected in
Cd7 and Cd12 cells after ER knockout indicating cadmium exposure may have altered
the regulation of these genes. Lastly, the effects of chronic cadmium exposure on
sensitivity to chemotherapeutic drugs were also investigated. We found that the
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cadmium-adapted cells were more resistant to taxane drugs than MCF7 cells, but showed
a similar response to anthracycline and antimetabolite drugs. Collectively, our findings
show that chronic cadmium exposure promotes breast cancer progression by increasing
the ability of breast cancer cells to adapt to the loss of ERα as well as highlight a
potential new role for chronic cadmium exposure in development of drug resistance.

ix

Acknowledgements
I would first like to thank my mentor Dr. Maggie Louie for her guidance
throughout this process. I would not have made it through this long and difficult journey
without her. At times our relationship was tumultuous, but I know that she ultimately
was pushing me to make me a better scientist and improve my work ethic. Above
everything else, it is evident that Dr. Louie has great passion for her students and always
has their best interests in mind. I know we have forged a lifelong relationship, and she
will always be a resource for me to consult in the future.
Next, I would like to thank Dr. Mary Sevigny for agreeing to be my second reader
and doing such a thorough and helpful job critically reviewing my thesis. I can safely say
that the final product was much improved by her revisions. She dedicated part of her
summer to review my thesis, which is a time-consuming project, so I could not be more
grateful. Dr. Meredith Protas is also worthy of praise for her work as the program
director. She did a wonderful job coaching us through the process and making sure we
had all the resources we needed to finish our theses. Additionally, she brought in useful
speakers and resources to help us reach the next step in our careers. I would also like to
thank all the members of the Louie lab—Hongye, Emily, Jenny, Karin, Candice, Brenda,
Erica, and Alexis—for the laughs and camaraderie. Hongye Zou, a former graduate
student, is especially acknowledged for all his help and support. The lab would not have
been the same without him there the first year.
Lastly, I would like to thank my family for everything they have done for me to
help me continue my education and achieve my goals. They are always a source of

x

inspiration and motivation when things seem rough. No matter what happens, I know my
parents and brother will be there for whatever I need and I love you all very much!

xi

1. Chapter 1
1.1 Breast cancer
Breast cancer accounts for about 25% of all cancers diagnosed among women
worldwide (1, 2). In the United States, it is projected breast cancer cases in 2018 will
account for 30% of all cancer cases, thus making it the most prevalent female cancer (3).
The estimated lifetime risk of developing breast cancer for women in the US is about
12%, and current estimates predict that this year over 40,000 women will die from breast
cancer—about 14% of all cancer-related deaths among women in the US (3).
Breast cancers are classified into distinct subtypes based on the presence or
absence of specific molecular biomarkers, including estrogen receptor alpha (ERα),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
Over 70% of breast cancers are ERα-positive (ERα+), making it the most prevalent
subtype (3); and 50-60% of breast cancers also express PR, while 5-10% express ERα
only (4, 5). ERα+ tumors typically are less aggressive and have a favorable prognosis
with a 5-year survival rate of over 90% (6). Additionally, a population-based study found
that breast cancers expressing ERα and PR are more likely to be diagnosed at stage I or
II, whereas tumors at more advanced stages are less likely to be ERα+/PR+ (7). The
effects of estrogen, a hormone involved in mammary gland development, are mediated by
the estrogen receptor and have been shown to stimulate breast cancer cell growth (8).
Therapeutic agents targeting the receptor and/or the synthesis of estrogen have shown
success in treating ERα+/PR+ and ERα+/PR- breast cancers (5, 9). Selective ER
modulators (SERMs) and selective ER down-regulators (SERDs) are drugs that
specifically target ERα and block estrogen binding (10), while aromatase inhibitors
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reduce the overall levels of circulating estrogen by blocking its synthesis. Accordingly,
patients with metastatic breast cancer expressing ERα have been shown to respond well
to hormone therapy and have higher rates of survival than those lacking ERα (11).
Clearly, ERα is a useful biomarker for the treatment as well as diagnosis of breast cancer.
Unlike ERα, HER2 is expressed in only 20-30% of all breast cancer cases (12).
HER2+ tumors are generally more invasive, have a worse prognosis, and are more likely
to recur and metastasize than ERα+/HER2- breast cancers (13-15). However, treatment
of this subtype has improved with the introduction of therapies targeted to HER2, like
trastuzamab—a monoclonal antibody that specifically binds to the extracellular domain
of HER2 to (a) inhibit HER2 receptor dimerization and downstream signaling and (b)
recruit immune cells to kill HER2+ tumor cells (16). A recent study carried out by Perez
and colleagues showed that HER2+ breast cancer patients treated with chemotherapy
alone had a 10 year survival rate of 75.2%, whereas patients treated with chemotherapy
plus trastuzamab had a 10 year survival rate of 84% and experienced a 37% increase in
overall survival (17).
Triple-negative breast cancers (TNBCs) do not express ERα, PR, or HER2, and
these tumors account for 10-20% of all breast cancer cases (12, 18, 19). Such tumors
tend to be the most aggressive and have the worst prognosis of all the breast cancer
subtypes (18-20). A study of TNBC patients found that 33% experienced distant
recurrence within 5 years of diagnosis compared to 20% in other breast cancer patients,
and the median time to death after recurrence was 9 months in TNBC patients and 20
months for non-TNBC patients (21). One-third of TNBCs are in either stage III or IV at
the time of diagnosis, and this subtype accounts for 15% of all invasive breast cancer (22,
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23). Chemotherapy is the most common form of therapy used in TNBC treatment, as
targeted therapies are not currently available for these types of tumors.
1.2 Breast cancer risk factors
Environmental and biological risk factors are both thought to play important roles
in the development of breast cancer. Biological risk factors that can contribute to the
development of breast cancer include genetics, gender, race/ethnicity, and lifetime
exposure to estrogen—the steroidal hormone responsible for the development of the
mammary gland and other female characteristics (2, 24). As indicated earlier, given its
role in mammary gland development and cell growth, the deregulation of estrogen
signaling plays a central role in the development of hormone-dependent breast cancers.
Lifetime estrogen exposure is influenced by the age at onset of menstruation, age at first
pregnancy, age at which a woman enters menopause, and obesity (25, 26).
Environmental risk factors include diet, cigarette consumption, physical activity, and
environmental exposures to chemicals and heavy metals (2, 27). Furthermore, exposure
to environmental agents that have estrogen-like activity may compound with lifetime
exposure to estrogen and contribute to breast cancer (28). In addition to pharmaceutical
and plant sources of estrogens, studies have suggested some heavy metals possess
estrogenic activity and may contribute to breast cancer (29). These heavy metals are
collectively referred to as metalloestrogens and include nickel, selenium, mercury, and
cadmium, the latter of which is the best characterized of all the metalloestrogens (29-31).
1.3 Cadmium
Cadmium is found ubiquitously in the environment. It is present in the earth’s
crust at a concentration of 0.1-0.5 ppm and is a natural component of ocean water with
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average levels as high as 110 ng/L in some coastal areas (32). Cadmium is primarily
released into the environment through the mining and refining of metals, the burning of
fossil fuels, and the disposal and incineration of waste. These activities can pollute the
soil and water and then enter the food supply by accumulating in plants and animals (33).
For non-smokers in the United States, dietary intake is the largest source of cadmium
exposure, with estimated daily intakes of 0.35 and 0.30 g Cd/kg/day for men and
women, respectively (34-36). Shellfish, wheat, potatoes, and leafy vegetables are foods
that tend to be higher in cadmium content. Each cigarette contains roughly 1.7 g Cd
and about 10% of this is inhaled when smoked. Accordingly, the cadmium burden of
cigarette consumers is greater than that of non-smokers, with mean blood cadmium levels
of 1.58 g/L and 0.38 g/L, respectively (37, 38). The body is only able to remove a
fraction of our daily cadmium intake, and consequently cadmium tends to bioaccumulate
in body tissues. As a result of such prolonged exposure, cadmium has a half-life in blood
of about 20-30 years (36, 39, 40). Cadmium has been recognized as a carcinogen by the
International Agency for Research on Cancer (IARC) and the U.S. Environmental
Protection Agency (EPA) (41). While the primary target organs for cadmium are the
kidney and lungs, other studies indicate that cadmium can also affect other tissues, like
the liver, prostate, and breast (42-46).
1.4 Epidemiological evidence connecting breast cancer and cadmium exposure
Several epidemiological studies link cadmium exposure and breast cancer. A
report by McElroy et al. measured urinary cadmium levels in 246 breast cancer patients
and 254 age-matched controls using inductively coupled plasma mass spectrometry.
They found that women with a higher cadmium burden had an increased risk of
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developing breast cancer compared to women with lower cadmium levels (47). A similar
study from Japan using flameless atomic absorption spectrometry showed that urinary
cadmium levels positively correlated with breast cancer risk (48). Strumylaite et al.
compared cadmium concentrations in the tissue, blood, and urine of 57 breast cancer and
51 benign tumor patients. The researchers revealed significantly higher cadmium levels
in the tumor tissue and urine of breast cancer patients than those with benign tumors (49).
Interestingly, this study also reported that ERα-positive breast cancers had significantly
higher cadmium concentrations than ERα-negative cancers (49), which suggests that
cadmium might be a more critical factor in tumors expressing ERα. A recent study
showed that the cadmium content of breast cancers increased the risk of distant
metastasis within the first 5 years (50). Conversely, two cohort-based studies could not
conclude higher cadmium levels increased the risk of breast cancer mortality based on
urinary cadmium measurements (51, 52), but this may be attributed to the small sample
sizes of the studies (n<45) (53). There are also inconsistencies in epidemiological reports
focusing on dietary cadmium exposure. While one report found that dietary cadmium
exposure increased the breast cancer risk of post-menopausal women (54), another study
based on self-reported surveys of food consumption in over 150,000 post-menopausal
women showed no significant association between dietary cadmium exposure and
ovarian, endometrial, and breast cancer risk (55). A study of dietary cadmium intake and
the risk of hormone-defined breast cancer in 405 Japanese women found a significant
association for ERα+ tumors in postmenopausal women (56). Finally, although a metaanalysis of previous studies on dietary cadmium exposure and breast cancer risk in postmenopausal women concluded there was no statistically significant association, the
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authors suggested interpretation of the data should be made cautiously due to the
difficulties in accurately determining cadmium intake from food consumption (57). All
these reports highlight the need of additional studies to better understand the relationship
between environmental cadmium exposure and breast cancer risk.
1.5 Animal and in vitro research on cadmium exposure and breast cancer
Research on the physiological and cellular effects of cadmium exposure have
provided more insights into its potential role in breast cancer. Two in vivo studies
demonstrated that ovariectomized rats subject to a single acute cadmium exposure
displayed increased uterine weight and higher density of epithelial cells in the mammary
gland, both of which are considered early events in breast cancer development (58, 59).
Johnson et al. also found that the effects of cadmium were blocked when the rats were
concurrently injected with a dose of the antiestrogen ICI-182,780, suggesting that ERα
may play an important role in mediating cadmium’s effects (58). Two in vitro studies
found that acute cadmium exposure upregulated the expression of ERα-regulated genes
and increased cell growth in ERα-positive MCF7 breast cancer cells (60, 61). Earlier
work from our lab has shown that cadmium promotes expression of cyclin D and cmyc—two genes involved in cell proliferation—by potentiating the interaction between
ERα and the transcription factors c-fos and c-jun (62). Although these studies support
cadmium’s role as a metalloestrogen in breast cancer, most humans are exposed to
cadmium at low, chronic levels, not acute.
Despite difficulties to accurately mimic environmental cadmium exposure at
minute quantities over prolonged periods of time, some studies have managed to examine
the effects of chronic cadmium exposure. For example, Alonso-Gonzalez et al. showed
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an increase in the uterine weight, ductal branching, and lobuloalveolar development in
ovariectomized mice after 7 weeks of low exposure to cadmium (63). Another report
demonstrated that prolonged exposure to cadmium malignantly transformed breast
epithelial cells in vitro, independent of ERα expression (64). Our lab has likewise
mimicked chronic cadmium exposure by exposing ERα-positive MCF7 breast cancer
cells to low levels of cadmium (100 nM CdCl2) for six months. We have found that the
cadmium-exposed MCF7 cells grow faster, have increased migration capabilities, and are
more invasive, indicating that chronic cadmium exposure promotes breast cancer
progression (65, 66). Our lab also demonstrated that low levels of cadmium promotes
expression of SDF1, a chemokine that promotes tumor growth and metastasis (67, 68) by
altering the interaction between ERα, c-jun, and c-fos, thus supporting cadmium’s
function as a metalloestrogen (65). Microarray analysis showed that the expression of
genes that impact many pathways—both ERα-dependent and -independent—was altered
in cadmium-exposed MCF7 cells (66). However, although chronic cadmium exposure
has been shown to increase the malignancy of breast cancer cells, the underlying
mechanisms that contribute to breast cancer development and progression are still not
fully understood.
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2. Chapter 2. The effects of chronic cadmium exposure on estrogen receptor gene
regulation and cancer phenotypes
2.1 Introduction
ER and ERβ, another estrogen target, belong to a superfamily of nuclear
hormone receptors that have a highly conserved structure (69, 70). Estrogen binds to the
ligand-binding domain (LBD) to initiate ligand-dependent transcriptional activation
within the activation function-2 domain (AF-2). The binding of estrogen also induces a
conformational change leading to dimerization and translocation into the nucleus. Once
inside the nucleus, this conformational change allows for its interaction with other
transcriptional cofactors (71, 72). The conserved DNA-binding domain (DBD) contains
two zinc fingers which bind to a specific palindromic sequence—5`GGTCAnnnTGACC-3`—called an estrogen response element (ERE) (73). Unlike the
DBD and LBD, the NH2-terminal is highly variable in sequence among the nuclear
receptors and contains the activation function-1 domain (AF-1), which is responsible for
ligand-independent activation of the receptor (74). While AF-1 and AF-2 have distinct
functions, both are crucial for the transcriptional activity of ER and often work
synergistically to induce a more robust transcriptional response (75).
ERs regulate gene expression and cellular processes through both genomic and
non-genomic actions (Figure 1). The genomic effects of ER signaling occur through both
classical and non-classical mechanisms. In the classical mechanism, ligand binding
activates ER causing homodimerization and translocation into the nucleus where it binds
directly to DNA to modulate expression of target genes (73). Classical ER-regulated
genes contain an ERE site upstream of the transcription start site that facilitates DNA
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binding and the recruitment of co-regulators by ER (76). Non-classical mechanisms are
not dependent on a full-length ERE (77). In this form of gene regulation, ER forms
heterodimers with other transcription factors to recognize half-ERE sites within promoter
regions. Alternatively, ER can be recruited by other transcription factors as a coregulator to alter gene expression independent of an ERE (78, 79). Transcription factors
that associate with ERα, such as Sp-1, AP-1, and the NFkB families of transcription
factors, are involved in regulating many cellular processes (80-84). ERs can also be
activated through post-translational modifications in the AF-1 region independent of
estrogen (74). Conversely, ERs can impact gene regulation without directly binding to
nuclear DNA. Such non-genomic actions of estrogen can be mediated by cross-talking of
cytosolic ER with other signaling pathways (85, 86) or through the membrane receptor
known as GPR30, which activates signaling cascades to elicit a physiological response
(87, 88).
Estrogen binds to the ER to regulate multiple physiological processes, including
growth and development of the mammary gland (89). Lifetime exposure to endogenous
estrogens is a key risk factor for breast cancer (25, 90), and exogenous agents with
estrogenic activity have also been implicated in breast cancer. The heavy metal cadmium
is an environmental pollutant that is known to have estrogenic activity (29).
Epidemiological studies have found that cadmium levels positively correlate with breast
cancer risk and tumor malignancy (47, 49). To better understand the estrogenic activity
of cadmium on breast cancer, multiple studies have attempted to delineate the molecular
interactions between cadmium and ERα. Stoica et al. measured the ability of cadmium to
bind and activate both wild-type and mutant forms of ERα transfected into COS-1 cells.
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This study revealed that cadmium activated ERα at concentrations as low as 10-11 M and
also blocked estradiol binding in a noncompetitive manner indicating that cadmium
interacts with ERα in the LBD (91). Another study carried out by Nesatyy and
colleagues used chemical modification of ERα to identify potential cadmium interaction
sites and found that cysteine residues within the LBD of the receptor have a strong
affinity for cadmium (92). However, cys-381 and cys-447, two amino acids implicated
as cadmium interaction sites previously (91), were not consistent with the cysteine
residues identified by Nesatyy et al. (92). Due to chemical similarities between Zn2+ and
Cd2+, the zinc fingers of the DBD are another potential interaction site between cadmium
and ERα. Accordingly, Predki and colleagues investigated the ability of several metals to
replace zinc in the zinc fingers of hormone receptors and its effect on DNA binding in
vitro. These studies demonstrated that even though ER and glucocorticoid receptor
(GR) were able to bind DNA even after cadmium displacement of zinc in the zinc fingers
of the DBD, cadmium substitution slightly increased the DNA binding affinity of ER
(93, 94). While it is unclear how cadmium modulates the activity of ERα, these
mechanisms may have implications relevant to breast cancer development.
Multiple studies, including those from our lab, have demonstrated that cadmium
mimics estrogen and induces expression of ERα target genes under conditions of acute
exposure to high concentrations (>1 µM) of cadmium (31, 60-62, 91, 95). In addition to
acute studies, our lab has also evaluated the impacts of chronic, low-level exposure to
cadmium on breast cancer and showed that prolonged exposure to cadmium even at low
levels (10-7 M) increases the malignancy of MCF7 cells (65). Furthermore, after
prolonged exposure to cadmium, the gene expression profile of these cells was altered
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(66). Despite evidence that cadmium has estrogenic activity and may activate ERα upon
acute exposure, less is known about the effects of chronic cadmium exposure on breast
cancer and whether the estrogenic activity at low exposure levels is necessary for disease
progression.
The goal of this project is to determine the role of ERα in chronic cadmiuminduced gene expression and breast cancer progression. To achieve this, we modulated
ERα expression in MCF7 breast cancer cells chronically exposed to cadmium and
examined the effects on gene expression and phenotypic characteristics. Our results
demonstrate that although ERα plays an important role in cadmium-mediated gene
expression alterations and malignant phenotypes, chronic exposure to cadmium also
increases the ability of MCF7 cells to adapt to the loss of ERα and aid in cell survival.
2.2 Materials and Methods
Materials
MCF7 cells were obtained from American Type Culture Collection (ATCC Manassas,
VA). Cadmium chloride (Acros Organics, Geel, Belgium) was dissolved in autoclaved
H2O and sterile-filtered to make a 1M solution. Stock solution of ICI-182, 780 (Tocris
Bioscience, Bristol, UK) was prepared at a concentration of 10-3 M in DMSO according
to manufacturer’s protocol.
Cell culture
MCF7 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Life
Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS)
(Hyclone, Logan, UT) and 1% penicillin and streptomycin (P/S) (Life Technologies).
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Cadmium-adapted cell lines, MCF7-Cd7 and -Cd12, were generated as described
previously (65, 66) and maintained in DMEM with 10% FBS, 1% P/S, and 10-7 M CdCl2.
Identifying differentially expressed (DE) genes
Total RNA was collected from cells treated with 10-7 M of the antiestrogen ICI-182,780
or vehicle using Trizol Reagent (Life Technologies) and columns from the Direct-zol
RNA MiniPrep kit (Zymo Research Corporation, Irvine, CA) according to the
manufacturer’s protocol. Triplicate samples were sent to the bioinformatics core at the
University of Minnesota Genomics Center. After passing quality check, mRNA was
isolated from the total RNA via oligo-dT purification. This was followed by randomprimed reverse-transcription, second-strand cDNA synthesis, and creation of a strandspecific library from the resulting dsDNA. The 50 bp paired-end reads were sequenced
on a HiSeq 2500 (Illumina, Hayward, CA) at a depth of 22,000 reads. EdgeR (96) was
used to determine DE genes and the resulting list of genes was ranked by false discovery
rate (FDR) ranging from 10-3 to 10-6. Different subsets of data were compared using Perl
scripts (www.perl.org). Cluster 3.0 (97, 98) was used to organize data sets by DE genes,
and heatmaps highlighting top 500 genes were created using
http://jtreeview.sourceforge.net/.
RNA interference
Approximately 1x105 cells were seeded into 6-well plates and transfected the following
day with ER siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) using siRNA
transfection reagents (Santa Cruz Biotechnology). A scrambled siRNA (Santa Cruz
Biotechnology) was used as a control. The following day, the medium was replaced with
DMEM containing 10% FBS and 1% P/S. Cells were harvested 24 and 48 hours later for
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gene and protein expression analysis using reverse transcriptase PCR (qRT-PCR) and
western blot, respectively.
Antiestrogen treatment
Approximately 2x105 cells were seeded into 6-well plates and treated with a final
concentration of 10-7 M ICI-182,780 or mock-treated with DMSO (Sigma Aldrich, St.
Louis, MO). Cells were harvested 24 and 48 hours later for gene and protein expression
analysis using qRT-PCR and western blot, respectively.
Western blot analysis
Cells were lysed in 1% sodium dodecyl sulfate (SDS)-HEPES buffer (0.05 M HEPES,
1% Triton, 0.002 M EDTA, 1% Deoxycholate, 0.002 M EGTA, 0.15M NaCl, and 0.01 M
NaF) plus protease inhibitor cocktail (Thermo Fisher, Waltham, MA) for 15 minutes at
4C. The cell lysate was then centrifuged at 20,000 x g for 15 minutes at 4C. The total
protein concentration was determined using the Bio-Rad Dc Protein Assay kit (Bio-Rad,
Inc., Hercules, CA). Proteins were separated using SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore,
Hayward, CA). The membranes were blocked with 5% milk-Tris-buffered saline with
Tween (TBST) for one hour before protein expression was monitored using the following
specific antibodies at dilutions ranging from 1:500 to 1:1000: ER Ab-12 (6F11)
(Neomarkers, Fremont, CA), Cathepsin D (C-5; Santa Cruz), SDF1 (Cell Signaling
Technology), c-myc (D84C12; Cell Signaling Technology), Cyclin D (A-12; Santa
Cruz), and Actin [AC-15] (Sigma). HRP-goat anti-mouse and -rabbit secondary
antibodies (Invitrogen, Carlsbad, CA) were used at a concentration of 1:2000, and Clarity
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Western ECL Substrate (Bio-Rad) was used for detection. Images were captured and
analyzed using the iBright CL1000 imager (Invitrogen).
Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated from cells using Trizol reagent (Life Technologies) and columns
from the Direct-zol RNA MiniPrep kit (Zymo Research Corporation, Irvine, CA)
according to the manufacturer’s protocol. One microgram of total RNA was converted to
cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems, Inc., Foster
City, CA). Gene expression was quantified using gene specific primers and Fast SYBR
Green master mix (Applied Biosystems). The reaction was cycled 40 times with an
annealing temperature of 60ºC. All gene-specific primers were synthesized by Integrated
DNA Technologies, Inc. (IDT, San Diego, CA).
Table 1.
c-mycF
c-mycR
cyclin D1F
cyclin D1R
CTSDF
CTSDR
SDF1F
SDF1R
pS2F
pS2R
ActinF
ActinR

qRT-PCR Primer Sequences (5  3)
CTCCACACATCAGCACAACT
GTTTCCGCAACAAGTCCTCT
AATGTGTGCAGAAGGAGGTC
GAGGGCGGATTGGAAATGAA
CTCTGTCCTACCTGAATGT
GACAGCTTGTAGCCTTTG
GTCAGCCTGAGCTACAGATGC
CACTTTAGCTTCGGGTCAATG
GCGCCCTGGTCCTGGTGTCCA
GAAAACCACAATTCTGTCTTTC
GAGAAAATCTGGCACCACACC
ATACCCCTCGTCGATGGGCAC

Luciferase Reporter Assay
The ERE-Luc reporter plasmid contained an insert with three tandem ERE sequence
repeats upstream of the TATA promoter and the sequence encoding a functional
luciferase on a pGL-3 plasmid. An empty pGL-3 vector was used as a control.
Approximately 2.5 x 104 cells were seeded in 24-well plates and allowed to grow
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overnight. The following day, transfection with ERE-Luc or empty pGL3 plasmids along
with the pRL-SV40 Renilla luciferase plasmid (Promega) was accomplished using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Five hours
after transfection, the medium was changed to DMEM containing 10% FBS and 1% P/S,
and cells were harvested 24 hours later. ICI-182,780 was added at a final concentration
of 100 nM. Assays were performed in triplicate and analyzed using the DualGlo Dual
Luciferase Assay system (Promega, Madison, WI).
Derivation of CRISPR/Cas-9-edited cell lines
Approximately 1x105 cells were seeded into 6-well plates and transfected with ER
double nickase plasmids (Santa Cruz Biotechnology). To select for successfully
transfected cells, 2.5 g/mL puromycin (Santa Cruz Biotechnology) was added to the
media for three days. Single cell clones were isolated by serial dilution in 96-well plate,
and wells with only a single cell were expanded into clonal cell lines. Cell lines were
initially screened for ER protein expression by western blot analysis using an ERspecific antibody (Ab-12, Neomarkers). Clones that did not express ER at the protein
level were candidates for DNA sequencing verification performed by Genewiz, Inc.
(South Planfield, NJ). Sequence reads of ~800bp spanning the target region in the first
exon of ESR1 were aligned using MacVector software (MacVector, Inc., Version 12.7.0
(214), Apex, NC) to identify frameshift mutations.
Cell Growth Assay
Approximately 50,000 cells were plated in 6-well plates. The next day, cells were
counted in triplicate using a hemacytometer (Thermo Fisher), and total cell number was
counted 2, 3, and 4 days later after the initial cell count. The doubling times were
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determined using the exponential growth equation in Graphpad Prism v7.02 software
(GraphPad Software, Inc., San Diego, CA).
Scratch Wound Assay
Cells were allowed to grow to approximately 80-90% confluence in 6-well plates before
being scratched with a P200 pipette tip. The wound was imaged on the same day (day 0)
and again after 4 days of growth (day 4). To quantify the migration capability of the
cells, the surface area of the wound at day 0 and 4 was calculated using ImageJ software
(NIH, Bethesda, MD). The percent of the wound that was healed was calculated using
this equation:
% wound repaired = [1-(wound surface area day 4/wound surface area day 0)] x 100
Soft Agar Colony Formation Assay
Twenty-four well plates were coated with 1 mL 1% agar in supplemented DMEM with
20% FBS and 2% P/S, and this constituted the bottom later of the well. Once solidified,
approximately 500 cells were mixed with 0.5 mL 0.6% agar DMEM containing 10% FBS
and 1% P/S and poured on top of the bottom layer and incubated at 37C and 5% CO2.
Fresh media was added to the top layer every 2-3 days. After two weeks, live colonies
were stained using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide;
Invitrogen) and imaged using the ChemiDoc Imaging system (Bio-Rad). Colonies of 100
cells or greater were counted.
Statistical Analysis
To determine statistical significance, all data were analyzed using an unpaired, two-tailed
T test in Graphpad Prism.
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2.3 Results
While our lab previously demonstrated that breast cancer cells chronically
exposed to cadmium had altered gene expression profiles in comparison to parental
cells—including estrogen-responsive and breast cancer-associated genes (66)—the role
of ERα in mediating these changes is unclear. To determine if chronic cadmium
exposure alters gene expression through ERα-dependent mechanisms, MCF7 cells and
cadmium-adapted cells (Cd7 and Cd12) were treated with the antiestrogen ICI-182,780
(ICI) to downregulate ERα, and a non-biased global gene expression analysis was
conducted using RNA sequencing (RNA-seq) (University of Minnesota Genomics
Center, Minneapolis, MN). Figure 2A shows the hierarchical clustering of the top 500
differentially expressed (DE) genes (FDR ≤ 10-6), demonstrating that the reduction of
ERα alters expression of many genes in both MCF7 and the cadmium-adapted cell lines,
including many of the ERα-regulated genes, such as GREB1, PR, SDF1, MYC, IGF1R,
CTSD, NRIP1, and PRSS23 (65, 66, 91, 99). Moreover, under normal conditions (in the
absence of ICI) these genes appear to be upregulated in the cadmium-adapted cells
compared to the MCF7 cells, suggesting that chronic cadmium exposure alters expression
of these ERα-regulated genes (Figure 1A). In total, the RNA-seq analysis identified
3,706, 4,721, and 4,628 DE genes in MCF7, Cd7, and Cd12, respectively, when treated
with ICI compared to mock treated cells. Of the DE genes, 2,477 are shared by all three
cell lines, while 251, 981, and 1,314 were unique to MCF7, Cd7, and Cd12, respectively
(Figure 2B). In all, 67.3% and 59.5% of the DE genes in Cd7 and Cd12 cells,
respectively, were shared with MCF7 cells suggesting that ERα continues to play an
important role in gene expression after prolonged cadmium exposure.
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To better understand how chronic cadmium exposure affects ERα-regulated
genes, we compared how the classical ERα (ERE) genes and ERα-responsive (ERR)
genes (100, 101) were altered after antiestrogen treatment in the MCF7 and cadmiumadapted cells. The results in figure 2C show that there were 180 total ERE genes that
were altered by ERα modulation. Of those, 138 ERE genes (76.7%) were changed in the
same direction (either up- or down-regulated) in MCF7, Cd7, and Cd12 cells (Figure 2C).
As for the ERR genes, 428 (53.6%) of the 799 genes were altered in the same direction
for all three cell lines (Figure 1D). There were only 17 ERR genes that were only
differentially expressed in MCF7 after ICI treatment, while 89 and 98 ERR DE genes
were unique to Cd7 and Cd12, respectively (Figure 2D). These findings show that while
a majority of ERE genes responded in the same manner to decrease levels of ERα, more
variability existed within the ERR genes, suggesting that chronic cadmium exposure may
have expanded the function of ERα.
To confirm the RNA-seq data, ERα expression was down-regulated by either
RNA interference (RNAi) or ICI for 24 and 48 hours, and cells were collected for protein
and gene expression analyses. Consistent with the RNA-seq analysis, the expression of
the ERα target genes SDF1, CTSD, c-myc, and cyclin D1 were decreased in all three cell
lines at both the protein (Figure 3A) and transcription levels when ERα function was
impaired (p<0.05; Figure 3B). To assess the ability of ERα function to mediate the
transactivation of an ERE promoter, we transfected an ERE-luciferase reporter plasmid
into MCF7, Cd7, and Cd12 cells and measured the transcriptional output. Once again,
ERα expression was modulated by treating cells with and without ICI. Results in figure
3C show that transactivation decreased 58-, 47-, and 112-fold in MCF7, Cd7, and Cd12
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cells, respectively, after a decrease in ERα levels (p<0.01) suggesting that the loss of ERα
activity had a similar effect on MCF7 and Cd7 cells, but appears to have a slightly greater
effect on Cd12 cells. As expected, cells transfected with a control, empty pGL-3 plasmid
exhibited little to no activity in the absence or presence of ICI. Collectively, these
findings demonstrate that the loss of ERα results in significant reduction of ERE
transcriptional activity and alteration of estrogen responsive gene expression in the
cadmium-adapted cells.
Since ERα function remains intact after chronic cadmium exposure, we
questioned whether ERα is responsible for the cadmium-induced malignant phenotypes
(65). To test this, we developed a stable system of ERα loss using the CRISPR/Cas9
gene editing system to permanently knockout ERα expression. In brief, two short-guide
CRISPR RNA oligonucleotides were used to specifically target adjacent sequences in
exon 1 of the ESR1 gene (Figure 4A). Upon recognition of these target sequences, the
mutant Cas9 enzyme nicks both strands of DNA to induce a double strand break with
minimal off-target effects (102). Correction of this break by non-homologous end
joining often introduces insertions or deletions of nucleotides, which may lead to
permanent loss of gene function. DNA sequencing and protein expression analysis of the
MCF7, Cd7, and Cd12 CRISPR-edited clones revealed that 8 contained mutations that
resulted in a lack of ERα protein expression (Figure 4B-C), and these clones were
selected for further characterization. Clones that still expressed ERα of either the same or
different molecular weight were not used for further experimentation.
To confirm that ERα function is absent in the CRISPR-edited clones, ERα
transactivation was measured in clones transfected with ERE-Luc reporter plasmids and
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then treated with ICI for 24 hours. Figure 4D shows the MCF7, Cd7, and Cd12 control
cell lines that express ERα exhibited 94-, 46-, and 55-fold increase in ERE activity,
respectively, compared to cells treated with ICI (p<0.01), confirming ERα activity. On
the other hand, the transcriptional activity of the ERE-Luc promoter was significantly
reduced in all ΔERα clones relative to the unedited parental controls (p<0.01). Although
several clones exhibited above background levels of ERE transactivation activity in
comparison to their ICI-treated counterparts (2- to 6-fold difference; p<0.05), this activity
was 40- to 92-fold lower than the wildtype ERα activity in unedited parental cells (Figure
4D). To verify ERα was not significantly expressed in these clones, protein expression
analysis was repeated and again showed no ERα expression (data not shown), suggesting
that other nuclear hormone receptors and/or estrogen-related receptors (ERβ) that are also
sensitive to ICI may be activating the promoter. These data provide further evidence that
each of the CRISPR/Cas9-edited clones lost wildtype ERα function.
To investigate how the complete loss of ERα affects the phenotypes of MCF7 and
cadmium-adapted cells, we measured the doubling times for all the clones lacking ERα
(ΔERα) compared to control cells by determining the total cell number after 0, 48, 72,
and 96 hours. For statistical analysis, all three MCF7-ΔERα clones (C10, C22, and C24)
served as biological replicates, while the three Cd7-ΔERα (C7, C9, and C11) and two
Cd12-ΔERα (C16 and 17) clones were biological replicates of cadmium-adapted, ERα
knock-out cells. The average doubling time of the MCF7-ΔERα group was about 37
hours, which was significantly longer than the 24 hour doubling time of normal MCF7
cells (p<0.0001). The average doubling time for the Cd-ΔERα clones was 28.2 hours
compared to 21.4 hours for the cadmium-adapted group (p<0.0001; Figure 5A).
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Consistent with previous data (65), results in figure 5A show that the cadmium-adapted
cells grew faster than the MCF7 (24 vs 21.4 hours; p<0.05). Interestingly, despite the
loss of ERα, Cd-ΔERα clones retained a significant growth advantage over the MCF7ΔERα cells (28.2 vs 37 hours; p<0.0001) (Figure 5A).
To understand if depletion of ERα affects the ability of cadmium-adapted cells to
migrate, we used a scratch wound assay. In brief, cells were grown to 80-90%
confluence, a scratch wound was inflicted to the monolayer, and the ability of the cells to
repair the wound was monitored over 4 days. The surface area of the wound was
calculated using ImageJ software at day 0 and day 4, and the results in figure 5B and C
show that both the wounds in the MCF7 and cadmium-adapted cells were almost fully
healed by day 4, while this ability was reduced in Cd-ΔERα and even more significantly
impaired in MCF7-ΔERα. More specifically, the MCF7 cells had a wound healing
capacity of 70.4% compared to 36.2% for the MCF7-ΔERα cells (p<0.0001), while Cdadapted cells had a wound healing capacity of 72.6% compared to 54% for the Cd-ΔERα
cells (p<0.0001; Figure 5B-C). Although the slight increase in the migration potential of
the cadmium-adapted cells relative to MCF7 cells was not significant, the wound healing
capacity of the Cd-ΔERα clones was significantly greater than that of the MCF7-ΔERα
clones (p<0.01; Figure 5B). As with cell growth, ERα is important for wound healing,
though in the absence of ERα the cadmium-adapted cells still exhibit a greater migration
potential.
Given the differences observed in both growth and migration between MCF7ΔERα and Cd-ΔERα clones, we assessed tumorigenic potential using a colony formation
assay in soft agar. For each clone, approximately five hundred cells were seeded in soft
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agar, and colonies of approximately one hundred cells were counted after two weeks.
Results in figure 5D and E show an average number of 19 colonies formed by MCF7
cells which decreased to an average of 2.5 colonies in the MCF7-ΔERα clones
(p<0.0001), while the Cd cells formed an average of 27 colonies in soft agar compared to
4.3 colonies formed by the Cd-ΔERα clones (p<0.0001). The Cd-adapted cells formed
significantly more colonies than the MCF7 cells (p<0.01), which confirms previous
findings (65) that prolonged cadmium exposure enhances the malignant characteristics of
breast cancer cells. While the different number of colonies between Cd-ΔERα and
MCF7-ΔERα cells was not statistically significant, it was trending towards significance
with a p-value of 0.064 (Figure 5D). These findings confirm that chronic cadmium
exposure increases tumorigenic potential of breast cancer cells. Collectively, the
phenotypic analyses—growth, migration, and anchorage independency—demonstrate the
importance of ERα for these cancer characteristics. However, despite the loss of ERα,
the cadmium-adapted cells retained a growth and migration advantage over MCF7 cells,
suggesting that chronic cadmium exposure enables breast cancer cells to better adapt to
the loss of ERα.
Since our phenotypic assays highlighted significant differences in the
characteristics of the cadmium-adapted cells upon permanent loss of ERα, we decided to
further investigate how permanent loss of ERα in Cd-adapted cells affected the
expression of ERα-regulated genes. Specifically, we analyzed the transcriptional
expression of three classical (CTSD, pS2, and SDF1) and two non-classical (c-myc and
cyclin D1) ERα-regulated genes using reverse transcriptase PCR (qRT-PCR). Results in
figure 6A reveal that mRNA levels of CTSD, pS2, and SDF1 were significantly reduced
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in all ΔERα (MCF7, Cd7, and Cd12) clones (p<0.0001; Figure 5A)—consistent with the
transient ERα depletion (Figure 3). Curiously, although the results also show that the
gene expression of c-myc and cyclin D1 were significantly downregulated in the MCF7ΔERα cells (p<0.01), there was no significant difference in the expression observed with
either gene in the Cd7-ΔERα cells (Figure 6A), which was not quite consistent with
results in figure 3B. For the Cd12-ΔERα cells, c-myc expression was also not
significantly altered, though a decrease in cyclin D1 expression was seen but not as
significant compared to the decrease seen in MCF7-ΔERα cells (p<0.05 vs. p<0.01)
(Figure 6A). Similar to earlier experiments, these findings demonstrate that ERα,
whether transient (Figure 3) or permanent (Figure 6A) loss, is critical for the expression
of classical ERα genes in all three cells lines; however, the cadmium-adapted cells appear
to have an increased ability to continue expressing non-classical ERα genes after
permanent loss ERα, whereas this was not observed under transient reduction of ERα.
2.4 Discussion
As stated previously, epidemiological reports have found a link between cadmium
and breast cancer risk and malignancy (47, 49, 50). Animal models have also shown
cadmium promotes early signs of cancer development in the mammary gland and uterus
(58, 59, 63). Although multiple in vitro studies have shown that acute levels of cadmium
can mimic the effects of estrogen and activate ERα to alter expression of target genes
(60-62, 65), whether or not ERα is activated in response to the relatively low,
environmental levels of cadmium is unclear. Since our lab previously demonstrated that
chronic cadmium exposure is associated with a distinct gene expression “signature”—
which includes differences in estrogen responsive genes—we further investigated the
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role of ERα in mediating cadmium-induced gene expression and breast cancer
progression. Results from this study extend our earlier observations that chronic
cadmium exposure alters expression of ERα-regulated genes, including PRSS23, CTSD,
c-myc, and SDF1 (66), and upon transient reduction of ERα by antiestrogen treatment,
the expression of these genes was decreased (Figure 2A and B). Additionally, over half
of all the DE genes in response to ICI were shared in the three cell lines suggesting ERα
plays a critical role in gene regulation even after prolonged exposure to cadmium (Figure
2B).
While it is expected that ERα modulation would affect the expression of estrogen
responsive genes (99), a larger number of genes were impacted by the decrease in ERα
levels mediated by ICI in the cadmium-adapted cells. The RNA-seq results also revealed
that there was more variability in how ERR genes were impacted in the cadmium-adapted
cells in response to the reduction in ERα levels with only 53.6% of the ERR genes altered
in the same direction in all three cell lines as compared to 76.7% of ERE genes (Figure
2C-D). Notably, Cd7 and Cd12 had 89 and 98 ERR genes, respectively, that were
differentially expressed after ICI treatment and not shared by any other cell line
compared to only 17 in parental MCF7 cells. We speculate that prolonged cadmium
exposure may have deregulated ERα and expanded its function. Since cadmium has been
shown to displace other divalent metals, like zinc and calcium—both of which are
involved in ERα function—cadmium could bind to ERα and affect its transcriptional
capabilities (93, 103). Furthermore, difference in ERα function were also observed in
Cd7 and Cd12 (Figure 3), which is expected since these cell lines were derived from
single cells from a pooled population of MCF7 cells chronically exposed to cadmium.
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Future experiments to examine ERα transactivation in the pooled population of cadmiumadapted MCF7 cells and/or additional Cd lines would provide more insight into whether
this difference is unique to Cd7 and Cd12. Given the gene expression alterations in the
cadmium-adapted MCF7 cells, future studies to determine if global ERα promoter
occupancy in breast cancer cells is altered by chronic cadmium exposure would be
interesting.
Of course, it is possible that these differences in gene expression are not
dependent on direct interactions between cadmium and ERα. Since ERR genes are coregulated by other transcription factors (i.e. AP-1, Sp-1) in partnership with ERα (78, 79),
alterations in the expression or activity of these transcriptions factors in the cadmiumadapted cells could explain the differential response of ERR genes to ERα depletion.
Hart and colleagues reported that during cadmium adaption in lung epithelial cells, the
DNA binding activities of AP-1, EGR-1, and NFkB were increased, whereas the binding
activity of Sp-1 was reduced (104). Cadmium is also known to induce oxidative stress,
which can alter the expression of stress response genes, such as metallothioneins, heat
shock proteins, glutathione, and various transcription factors (105, 106). Similar to our
lab’s results with chronic cadmium exposure (65), Mahalingaiah et al. found that chronic
oxidative stress upregulated pro-metastatic genes and increased the tumorigenicity of
breast cancer cells (107). Thus, overall gene expression in the cadmium-adapted cells
might respond differently to antiestrogen treatment because their ability to react to stress
has been enhanced by chronic cadmium-induced oxidative stress.
In addition to the molecular changes, phenotypic differences in how MCF7 and
Cd-adapted cells respond to the loss of ERα were also observed. Consistent with past
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results, this study confirmed that the cadmium-adapted MCF7 cells grew faster than
parental MCF7 cells (Figure 5A). However, this study showed only minute differences
in migration between MCF7 and cadmium-exposed MCF7 which were not significant as
we had shown previously (65). This discrepancy may be explained by the fact that the
prior study was performed on a pooled population of MCF7 cells after chronic cadmium
exposure, and migration was examined after three days of growth; whereas clonal, singlecell derived lines were analyzed in this study and migration was assessed after a 4-day
period.
To further examine the impact of ERα loss on the malignant characteristics of
both MCF7 and Cd-adapted cell lines, a colony formation assay was used. After weeks
of growing in soft agar, Cd-adapted cells displayed a higher frequency of colony
formation in comparison to MCF7 cells (Figure 5D-E). Our results further establish that
Cd-adapted cells possess a greater tumorigenic potential with an increased ability to grow
in an anchorage-independent manner. While the loss of ERα negatively impacted the
tumorigenic potential of both MCF7 and Cd-adapted cells, the impact was slightly less on
the Cd-adapted cells. Our results confirmed and extended the observation—made by our
lab and others—that low levels of cadmium over prolonged periods of time induces
cancer progression (43, 44, 65, 108, 109). We speculate that chronic cadmium exposure
may also increase the ability of breast cancer cells to better adapt to stresses like ERα
loss. While more in-depth molecular and biochemical studies are necessary to uncover
the mechanistic underpinnings, initial gene expression analysis demonstrate that the
levels of the non-classical ERα-regulated genes, c-myc and cyclin D1, were less affected
by deletion of ERα in the cadmium-adapted cells in comparison to MCF7 cells (Figure
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6). Interestingly, c-myc and cyclin D1 expression were downregulated in MCF7, Cd7,
and Cd12 cells after transient modulation of ERα expression using either ICI or RNAi
(Figure 3A-B). This difference may be attributed to either the lack of a complete loss of
ERα under the transient condition or the fact that transient reduction of the receptor does
not allow for the cells to adapt to the change, unlike the permanent knockout of ERα
using CRISPR/Cas9.
Although our findings establish that ERα remains critical for the maintenance of
cadmium-induced malignant phenotypes in MCF7 cells, the cadmium-adapted breast
cancer cells seem to have developed an additional mechanism by which they can partially
circumvent the loss of ERα and continue to thrive. Confirmation of this hypothesis is
found in a study by Benbrahim-Tallaa et al., in which the authors concluded that the
estrogenic effects of cadmium were not necessary for carcinogenesis after prolonged
cadmium exposure malignantly transformed MCF10A cells, an immortalized normal
breast epithelial cell line that does not express ERα (64). In line with previous
observations (110-113), our study does not dispute that cadmium induces changes
independent of ERα, but also offers support that when present, ERα plays a critical role
in cancer progression. Further investigation of how chronic cadmium exposure may
change and expand the function of ERα could potentially identify additional mechanisms
by which cadmium functions as a metalloestrogen. Our findings that chronic cadmium
exposure stimulates the expression of estrogen-responsive genes and increases the
malignancy of breast cancer cells demonstrate that cadmium likely promotes breast
cancer progression through both estrogen-dependent and -independent pathways. In
conclusion, this study shows that chronic cadmium exposure reduced their dependency
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on ERα and increased the adaptability of breast cancer cells, which could have important
implications regarding the use of antiestrogen therapy against ERα+ breast cancers with
higher levels of cadmium.
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3. Chapter 3
3.1 Introduction
Chronic cadmium exposure has been shown to transform normal breast epithelial
cells and enhance the progression of malignant tumors (44, 106, 108, 109, 114, 115).
Abshire et al. demonstrated that when transformed rat myoblast cells were repeatedly
exposed to cadmium and then inoculated into immunodeficient mice, the resultant tumors
were more malignant and invasive compared to unexposed controls (108). Another study
showed that human fibrosarcoma cells chronically exposed to cadmium displayed more
aggressive behavior by readily invading reconstituted basement membranes (109). In
rats, repeated cadmium exposure at low doses resulted in more malignant and metastatic
tumors than rats treated with higher, acute dosages of cadmium (44). Cadmium exposure
has also been found to alter host-tumor interactions (115) and promote epithelial-tomesenchymal transition (EMT) (113), both of which may increase the invasiveness of
tumors, often observed after prolonged cadmium exposure. Additionally, our lab has
shown that breast cancer cells chronically exposed to cadmium for over six months have
higher growth rates, increased migratory ability, and enhanced invasiveness (65). These
findings not only suggest that cadmium can promote tumor progression, but that human
cadmium exposure may have important implications regarding cancer malignancy and
treatment.
Cadmium exposure may alter the effectiveness of certain anticancer drugs (116,
117). For example, Asara et al. demonstrated that treatment of normal MCF7 cells with
5-fluouracil (5-FU), an inhibitor of DNA synthesis and common breast cancer
chemotherapeutic, induced morphological signs of cytotoxicity, including swollen
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mitochondria, cell nuclei degeneration, and pore-like formations in the cell membrane
(116). However, when these cells were treated with an acute dose of cadmium (5 µM) in
addition to 5-FU, these morphological changes were no longer observed, suggesting that
cadmium may alter the response of MCF7 to 5-FU-treatment (116). In a follow-up study,
this group found that cadmium-exposed MCF7 cells had higher levels of bcl2 and lower
expression levels of p53, bax, and caspase-8 and -9 in response to 5-FU treatment, while
the reversed effect was observed in MCF7 cells treated with 5-FU but not exposed to
cadmium (117).
Although these findings indicate that acute cadmium exposure may inhibit the
cytotoxic effects of 5-FU, the effect of prolonged exposure to cadmium at low
environmental levels on the efficacy of certain chemotherapeutic drugs is not known. In
this chapter, we investigate the effects of chronic cadmium exposure on the sensitivity of
breast cancer cells to different classes of anti-cancer drugs, including antimetabolites,
anthracyclines, and taxanes. Our results suggest that breast cancer cells chronically
exposed to cadmium display a decreased response to the taxane drugs while exhibiting
little to no difference in response to doxorubicin and gemcitabine.
3.2 Materials & Methods
Materials
Cells were obtained or derived as described previously in Chapter 1. The following
anticancer drugs were obtained: cabazitaxel (Selleck Chemicals, Houston, TX),
docetaxel (Tocris, Bristol, UK), doxorubicin (Tocris), gemcitabine (Tocris), and 5fluouracil (Tocris). Drug stocks were diluted to 10-2 M or 10-3 M in either ethanol or
DMSO according to manufacturer’s protocol.
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Drug Response Assay
Approximately 1,000 cells were seeded in 96-well plates and treated the following day
with different concentrations of compounds: docetaxel (10-7-10-11 M), cabazitaxel (10-710-11 M), doxorubicin (10-6-10-10 M), and gemcitabine (10-6-10-10 M) for 48 hours. Cell
growth was measured indirectly using tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide) (Invitrogen) or [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium [MTS] (Promega). GI50
values (concentrations that inhibited 50% of cell growth) were plotted on a non-linear
regression of log-transformed data using GraphPad Prism v.7.02 (GraphPad Software,
Inc, La Jolla, CA) and expressed as mean ± SE.
Western Blot Analysis
Approximately 2 x 105 cells were seeded in 6-well plates and treated the following day
with varying concentrations of docetaxel or cabazitaxel for 24 hours. Cells were lysed
and samples processed as described previously in Chapter 1. Protein expression was
determined by incubation of the membrane with the following specific antibodies at
dilutions ranging from 1:500 to 1:1000—PARP (Cell Signaling Technology), p53 (Ab-6)
(Calbiochem, San Diego, CA), p21(12D1; Cell Signaling Technology), alpha-tubulin
(11H10; Cell Signaling Technology), and beta-tubulin (T4026; Sigma Aldrich). HRPgoat anti-mouse and -rabbit secondary antibodies (Invitrogen) were used at a
concentration of 1:2000 and Clarity Western ECL Substrate (Biorad) was used for
detection. Images were captured and analyzed using the iBright CL1000 imager
(Invitrogen).
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Annexin V Apoptosis Assay
Cell death was measured using the RealTime-GloTM Annexin V Apoptosis assay
(Promega) according to the manufacturer’s protocol. Briefly, approximately 2,500 cells
were plated in 96-well plates, and the following day triplicate samples were treated with
concentrations of cabazitaxel ranging from 10-7 to 10-11 M. The assay reagents were
added to each well immediately following drug treatment and incubated at 37ºC.
Luminescent readings were measured 36 and 48 hours later using the Fluorstar Omega
plate reader (BMG Labtech, Ortenberg, Germany). Half maximal effective concentration
(EC50) was determined with Graphpad Prism using a non-linear regression curve fit
algorithm.
Immunofluorescence
Approximately 1.5 x 105 cells were plated onto sterilized coverslips placed in 6-well
plates and treated the following day with cabazitaxel, gemcitabine, or vehicle control for
20 hours. Cells were fixed with acetone then permeabilized with 0.05% Saponin/PBS
and blocked with a 10% FBS/PBS solution. Anti-beta tubulin antibody (Sigma) was used
at a 1:300 dilution and was incubated for 1.5 hours. Alexa Fluor 488 secondary antibody
(Invitrogen) was used at a 1:200 dilution and was incubated for 1.5 hours. Slides were
mounted with Prolong Gold antifade reagent with DAPI (Invitrogen) and imaged using a
fluorescent microscope (Leica Microsystems, Inc., Deerfield, IL).
3.3 Results
To understand the effects of chronic cadmium exposure on drug sensitivity, a
panel of chemotherapies typically used in the treatment of breast cancer was selected.
This panel included microtubule-stabilizing agents, cabazitaxel and docetaxel (taxanes),
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the anthracycline doxorubicin, and antimetabolites gemcitabine and 5-fluorouracil. To
assess the potency of these drugs, we performed growth assays on control MCF7 and two
cadmium-adapted MCF7 clones (Cd7 and Cd12) to determine the drugs’ GI50, or the drug
concentration required to inhibit cell growth rate by 50%. The GI50 values for
doxorubicin were 429 nM, 282 nM, and 369 nM for MCF7, Cd7, and Cd12, respectively
(p>0.05), and for gemcitabine were 24.7 nM, 17.1 nM, and 19.4 nM, respectively
(p>0.05) (Fig. 7A). The GI50’s for 5-fluorouracil could not be determined because the
values were apparently above the highest concentration of the drug tested (10-5 M) for all
three cell lines. These results indicate no significant differences in how the three cell
lines responded to doxorubicin and gemcitabine. On the other hand, control MCF7 cells
and the cadmium-adapted cells showed significant differences in their responses to the
taxanes. More specifically, the GI50 values for cabazitaxel were 3.31 nM, 9.94 nM
(p<0.001), and 9.98 nM (p<0.001) for MCF7, Cd7, and Cd12, respectively, and 3.86 nM,
11.4 nM (p<0.0001), and 12.27 nM (p<0.0001) for docetaxel, respectively (Fig. 7A-B).
These findings indicate that chronic cadmium exposure alters the cells’ ability to respond
to taxanes and may promote resistance.
Since docetaxel and cabazitaxel are cytotoxic drugs that induce cell cycle arrest
and apoptosis, we analyzed the expression of proteins involved in these pathways to
evaluate if the cadmium-adapted cells are more resistant to taxane-induced apoptosis.
Results in figure 8A-B show the protein expression of poly(ADP-ribose) polymerase-1
(PARP1), p53, and p21—which are signals of either apoptosis or cell cycle arrest—in
MCF7, Cd7, and Cd12 cells 24 hours after treatment with increasing concentrations of
docetaxel and cabazitaxel (Fig. 8A-B). There were significantly higher levels of cleaved
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PARP1, a marker for apoptosis, in MCF7 cells treated with 1 nM of either drug compared
to Cd7 (p<0.05) and Cd12 cells (p<0.001) (Fig. 8A-C). Significant levels of PARP1
cleavage did not occur in the cadmium-exposed clones Cd7 and Cd12 until the cells were
treated with 5 nM and 10 nM, respectively, of the drugs (Fig. 8A-C). Additionally, in
MCF7 control cells, protein expression of p53 and p21, both of which are involved in cell
cycle arrest, increased by an average of 3.3- and 2.7-fold, respectively, in response to 1
nM of the taxane drugs. These increases were significantly higher than the 1.3- and 0.6fold change for Cd7, and the 1.4- and 1.6-fold change for Cd12 cells in p53 and p21
expression, respectively, after treatment with either docetaxel or cabazitaxel (Fig. 8A-C).
Consistent with the growth analysis, these results indicate that a higher concentration of
taxanes is necessary to promote the expression of proteins necessary to induce apoptosis
and cell cycle arrest in MCF7 cells chronically exposed to cadmium in comparison to
unexposed MCF7 cells.
As cells undergo apoptosis, the phospholipid phosphatidylserine (PS) translocates
from the inner to the outer leaflet of the cell membrane, and this can be detected in realtime using a luciferase-tagged annexin V recombinant protein. We analyzed the levels of
annexin V binding in order to provide a more quantitative measurement of apoptosis. To
assess the effects of the taxane cabazitaxel in promoting apoptosis in cadmium-adapted
cells, real-time exposure of PS on the outer leaflet of the cell membrane was observed 36
and 48 hours after treatment (Figure 8D). Since both cabazitaxel and docetaxel were
found to have similar effects on Cd7 and Cd12 cells and are known to have a similar
mechanism of action on breast cancer cells (118), we chose to focus on just cabazitaxel.
MCF7, Cd7, and Cd12 cells were treated with various concentrations (0.01 nM to 1 µM)
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of cabazitaxel, and the amount of PS translocation was detected by measuring
luminescence at 36 and 48 hours. Figure 8D shows an overall higher luminescent value
for MCF7 and a significant increase in PS translocation and annexin V binding at 1 nM
cabazitaxel after 36 hours, while an increase was not observed until 48 hours in
cadmium-adapted cells (Figure 8D). These data suggest that a larger number of MCF7
cells undergo apoptosis in response to cabazitaxel treatment compared to Cd7 and Cd12.
To determine the cells’ sensitivity to taxane-induced apoptosis, the concentration
required to induce 50% of PS and annexin V binding—or the half maximal effective
concentration (EC50)—was calculated based on the results shown in Figure 8D. After 48
hours of cabazitaxel treatment, the EC50 values were 0.27±0.1 nM, 1.02±0.08 nM
(p<0.01), and 0.90±0.07 nM (p<0.05) for MCF7, Cd7, and Cd12 cells, respectively
(Figure 8D). Collectively, these results support our growth and protein expression results
and demonstrate that chronic cadmium exposure promotes resistance to cabazitaxel and
necessitates a higher concentration to induce apoptosis.
Given that the mechanism of taxanes involves binding to microtubules to prevent
their disassembly, we evaluated the expression of alpha- and beta-tubulin, the monomer
components of microtubules, to understand how cadmium may alter the sensitivity to
taxanes (Fig. 9A). After 24 hours of cabazitaxel treatment, no significant alterations in
the expression levels of alpha- or beta-tubulin proteins were observed in MCF7, Cd7, or
Cd12 cells (Figure 9A). Since there was no significant difference in the expression of αand β-tubulin, we questioned whether the organization of β-tubulin was altered by
chronic cadmium exposure to promote the taxane-resistant phenotype. The microtubule
network of MCF7, Cd7, and Cd12 cells was visualized by immunofluorescent (IF)
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staining of β-tubulin (Fig. 9B). Cells were treated with 1 nM cabazitaxel, 100 nM
gemcitabine, or the vehicle control for 20 hours before being chemically fixed and
stained with β-tubulin-specific antibodies. During taxane-induced cell death, free tubulin
becomes overpolymerized to form shorter, highly bundled microtubules in a sheet-like
pattern (119). The IF images revealed that under normal conditions all three cell lines
had an expansive network of microtubules that branched throughout the cell body, but
after treatment with 1 nM cabazitaxel, the microtubule network of the MCF7 cells was
largely reduced compared to untreated cells, and β-tubulin was concentrated around the
nuclear periphery (Figure 9B). The effect on the microtubules was not as striking in the
Cd7 and Cd12 cells treated with 1 nM cabazitaxel. Instead, the microtubules of the
cadmium-adapted cells were well-distributed throughout the cell body similar to their
controls and did not shrink or localize around the nucleus to the same extent observed in
MCF7 cells (Figure 9B). Gemcitabine was used as a control since it has the same growth
inhibitory effects on all three cell lines and is known to block cancer growth via a
mechanism independent of microtubules. Results show a similar increase in cell size for
the MCF7 and cadmium-exposed cells in response to gemcitabine, but no differences in
the distribution and branching of microtubules were observed, as expected (Figure 9B).
These results indicate that the differential effects observed in MCF7 versus Cd7 and
Cd12 with cabazitaxel were specific and not associated with cytotoxicity or inhibition of
cell growth. These findings suggest that the microtubules of the Cd7 and Cd12 cells were
less impacted by cabazitaxel treatment and that chronic cadmium exposure enables the
cells to be less sensitive to the microtubule-stabilizing effects of the taxane drugs.
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3.4 Discussion
Animal and cell culture models have shown that prolonged cadmium exposure
can promote cancer progression (44, 49, 58, 64, 65), and acute exposure can inhibit the
activity of the anticancer drug 5-FU (116, 117). In this study, we investigated the effects
of chronic cadmium exposure on the sensitivity of breast cancer cells to different
chemotherapeutic drugs, including antimetabolites, anthracyclines, and taxanes. Our
results indicate that breast cancer cells chronically exposed to cadmium displayed a
decreased response to the taxane drugs, while exhibiting little to no difference in their
response to doxorubicin and gemcitabine (Figure 7). Although cadmium is recognized as
a carcinogen and associated with occupational cancer risk (106, 120, 121), its role in the
development and progression of breast cancer is still not fully understood, and
epidemiological associations between cadmium and breast cancer have been inconsistent
(47, 52, 55, 57). This current study demonstrates a potentially new role for chronic
cadmium exposure in promoting resistance to anticancer drugs and further highlights the
possible risks of prolonged environmental cadmium exposure in breast cancer.
In contrast to the cytotoxicity caused by antimetabolites and anthracyclines
through the inhibition of DNA and RNA synthesis, taxane cytotoxicity is mediated by the
drug binding to microtubules and preventing their disassembly (118, 122). Results in
figure 9A show no differences in the protein levels of either α- or β-tubulin, suggesting
that the mechanism of cadmium induced-taxane resistance is unlikely due to changes in
the expression of the microtubule subunits. Consistent with our findings, a previous
study by Ledda and colleagues demonstrated that cadmium exposure does not affect the
overall levels of α- and β-tubulin but rather induced tubulin posttranslational
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modifications (123). While this was not explored in our study, increased levels of
tyrosinated α-tubulin and differential expression of β-tubulin subtypes were found in
paclitaxel-resistant MCF7 cells (124), suggesting that the effect of chronic cadmium
exposure on posttranslational modifications should be evaluated further. We also
visualized β-tubulin localization before and after cabazitaxel treatment using IF (Figure
9B), and although no significant structural differences were observed between MCF7 and
cadmium-exposed cells in the absence of drugs, the microtubules of the untreated MCF7
cells were localized to the nuclear periphery, and the extensive branching throughout the
cytoplasm was decreased after cabazitaxel treatment (Figure 9B). This effect was not as
dramatic in the Cd7 or Cd12 cells, which suggests that chronic cadmium exposure may
decrease the sensitivity of microtubules to the stabilizing effect of cabazitaxel.
While our study shows that the response of microtubules to taxane treatment is
altered in cadmium-adapted cells, the mechanism of how cadmium mediates this effect is
unclear. O’Brien et al. demonstrated that calcium accelerates the rate of GTP hydrolysis
within the microtubule cap to destabilize growing microtubule ends without modulating
free tubulin levels (125). Interestingly, cadmium is known to behave similarly as other
divalent metals, like zinc, iron, and calcium (126), and multiple studies have shown that
cadmium destabilizes microtubules at concentrations of 10 µM and above (127).
However, these high levels are toxic to cells, causing alterations in cell morphology and
reduced cell fitness (128). An in vivo report found the microtubules of kidney cells were
highly irregular and diminished after repeated exposure to cadmium (129). Thus, higher
than normal intracellular cadmium caused by prolonged, chronic exposure may promote
microtubule disassembly by mimicking calcium, which could counteract the microtubule
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stabilizing effect of taxanes thus making breast cancer cells less sensitive to these drugs.
Lung cancer cells resistant to paclitaxel, another common taxane drug, had increased
microtubule dynamicity at rates 57-167% greater than paclitaxel-sensitive lung cancer
cells, suggesting that microtubule dynamics play a role in taxane-resistance (130).
Cadmium-transformed cells display diminished apoptosis (110, 131), and thus the
ability to suppress apoptosis is thought to be important in cadmium carcinogenesis (132,
133). While Cd7 and Cd12 less were less susceptible to taxane-induced cell cycle arrest
and apoptosis than control MCF7 cells (Figure 8), other studies indicate that apoptosis
resistance does not appear to be critical to cadmium-induced drug resistance, as the
cadmium-adapted cells are still sensitive to the apoptosis-inducing drugs doxorubicin and
gemcitabine (134-136).
Cadmium exposure and chemotherapy are both known to induce oxidative stress
(137-140), and chronic levels of oxidative stress have been shown to increase the
tumorigenic potential of breast cancer cells (107). Similarly, chronic cadmium exposure
may also promote breast cancer progression by persistently inducing sub-lethal levels of
oxidative stress, which may enable cells to adapt and tolerate other forms of stress, such
as anticancer drugs. Additionally, increased expression of metallothioneins, which are
metal-binding proteins upregulated in response to cadmium exposure (66, 141), has been
associated with resistance to certain drugs. We, too, have previously shown that chronic
cadmium exposure does increase expression of metallothioneins (66). Kelley et al. found
that overexpression of metallothionein-IIA conferred resistance to several antineoplastic
agents, but not 5-FU and vincristine (142). Since vincristine has a similar mechanism to
taxanes in that it targets the microtubules of the mitotic spindle to block cell division, this
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suggests that higher metallothionein levels may not play a prominent role in the
resistance to taxanes.
Contrary to our findings, Asara et al. demonstrated that cadmium exposure can
protect against the cytotoxic effects of 5-FU (116). However, this study used a cadmium
concentration 50-fold higher than the concentration we used, and unlike chronic
exposure, acute doses do not allow for the cells to adapt to cadmium. The study by Asara
and colleagues also did not evaluate differences in the growth rate of MCF7 cells treated
with 5-FU plus cadmium versus 5-FU alone. Since we were unable to determine the GI50
values for 5-FU in MCF7 and the cadmium-adapted cells (see Fig. 7A), further
investigation of the effects of cadmium on 5-FU response is definitely warranted.
In summary, the results of this study show for the first time that chronic cadmium
exposure increases resistance to taxane drugs. Specifically, cadmium-adapted cells are
less sensitive to taxane-induced apoptosis, cell cycle arrest, and microtubule stabilization.
Although the exact mechanism is still not clear, we speculate that higher intracellular
cadmium levels might decrease taxane potency by promoting microtubule disassembly to
counteract the stabilizing effects of the drug. However, it is likely that other pathways
are also involved, as chronic cadmium exposure causes MCF7 cells to become more
adaptable to stress (Chapter 1). Regardless of the mechanism, our findings do indicate
that breast cancer cells with a higher cadmium burden may be less responsive to taxanes,
and therefore these drugs may not be effective in treating ERα+ breast cancers that no
longer respond to hormone therapy. Patient cadmium levels can be measured through
blood, urine, hair, and tissue samples and have been shown to correlate with breast cancer
risk, tumor malignancy, and metastasis frequency, all which demonstrates cadmium’s
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potential as a biomarker in cancer (47, 49, 50). Fortunately, though chronic cadmium
exposure decreases the sensitivity of breast cancer cells to microtubule stabilizing agents
like taxanes, it appears to have little effect on the efficacy of drugs that target and block
DNA replication or RNA synthesis, indicating these might be better therapeutic options
for hormone-refractory breast cancer. Considering that taxanes are frequently prescribed
to breast cancer patients, the consequences of chronic cadmium exposure on taxane
resistance may have implications in predicting treatment success and the appropriate
selection of chemotherapeutic regimens in the future.
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